Terms: = Skin cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Clinical Outcome
427 results:
1. clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract] [Full Text] [Related]
2. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
5. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
6. Association of clinical manifestations of secondary lymphedema and lymph node dissection sites in the lower extremities of patients with melanoma.
Chae Woon P; Kim I; Kim JH; Hwang JH
Acta Oncol; 2023 Aug; 62(8):880-888. PubMed ID: 37656769
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
8. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract] [Full Text] [Related]
9. Mesenchymal Stem Cells and Regenerative Therapy with Bilateral Gracilis Flaps for Perineal Reconstruction of a Wound Infection in the Setting of Anal Squamous Cell Carcinoma.
Garcia MF; Tiwari KK; Gendreau JL; Burgess PL; Taupin P; Martin ED
Adv Skin Wound Care; 2023 Aug; 36(8):1-7. PubMed ID: 37471451
[TBL] [Abstract] [Full Text] [Related]
10. Effect of lidocaine spray on reliving non-coring needle puncture-related pain in patients with totally implantable venous access port: a randomized controlled trial.
Zhu Y; Niu S; Zhang Y; Zhang H; Chang J; Ye L
Support Care Cancer; 2023 Jul; 31(8):452. PubMed ID: 37421451
[TBL] [Abstract] [Full Text] [Related]
11. Functional outcomes and health-related quality of life following penile cancer surgery: a comprehensive review.
Croghan SM; Cullen IM; Raheem O
Sex Med Rev; 2023 Sep; 11(4):441-459. PubMed ID: 37204120
[TBL] [Abstract] [Full Text] [Related]
12. Flap perfusion assessment with indocyanine green angiography in deep inferior epigastric perforator flap breast reconstruction: A systematic review and meta-analysis.
Wang Z; Jiao L; Chen S; Li Z; Xiao Y; Du F; Huang J; Long X
Microsurgery; 2023 Sep; 43(6):627-638. PubMed ID: 37165852
[TBL] [Abstract] [Full Text] [Related]
13. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial.
Kent P; Haines T; O'Sullivan P; Smith A; Campbell A; Schutze R; Attwell S; Caneiro JP; Laird R; O'Sullivan K; McGregor A; Hartvigsen J; Lee DA; Vickery A; Hancock M;
Lancet; 2023 Jun; 401(10391):1866-1877. PubMed ID: 37146623
[TBL] [Abstract] [Full Text] [Related]
14. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas J; Martínez-Urbistondo D; Velázquez Kennedy K; Villares P; Barquin A; Dominguez A; Rodriguez-Moreno JF; Caro E; Suarez Del Villar R; Nistal-Villan E; Yagüe M; Ortiz M; Barba M; Ruiz-Llorente S; Quiralte M; Zanin M; Rodríguez C; Navarro P; Berraondo P; Madurga R
Front Immunol; 2023; 14():1156603. PubMed ID: 37143685
[TBL] [Abstract] [Full Text] [Related]
15. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract] [Full Text] [Related]
16. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
17. Type 2 Diabetes Mellitus and Efficacy outcomes from Immune Checkpoint Blockade in Patients with cancer.
Cortellini A; D'Alessio A; Cleary S; Buti S; Bersanelli M; Bordi P; Tonini G; Vincenzi B; Tucci M; Russo A; Pantano F; Russano M; Stucci LS; Sergi MC; Falconi M; Zarzana MA; Santini D; Spagnolo F; Tanda ET; Rastelli F; Giorgi FC; Pergolesi F; Giusti R; Filetti M; Lo Bianco F; Marchetti P; Botticelli A; Gelibter A; Siringo M; Ferrari M; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Ghidini M; Nigro O; Grossi F; De Tursi M; Di Marino P; Queirolo P; Bracarda S; Macrini S; Inno A; Zoratto F; Veltri E; Spoto C; Vitale MG; Cannita K; Gennari A; Morganstein DL; Mallardo D; Nibid L; Sabarese G; Brunetti L; Perrone G; Ascierto PA; Ficorella C; Pinato DJ
Clin Cancer Res; 2023 Jul; 29(14):2714-2724. PubMed ID: 37125965
[TBL] [Abstract] [Full Text] [Related]
18. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
[TBL] [Abstract] [Full Text] [Related]
19. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient clinical outcome.
Robinson ML; Morris CP; Betz JF; Zhang Y; Bollinger R; Wang N; Thiemann DR; Fall A; Eldesouki RE; Norton JM; Gaston DC; Forman M; Luo CH; Zeger SL; Gupta A; Garibaldi BT; Mostafa HH
Clin Infect Dis; 2023 May; 76(9):1539-1549. PubMed ID: 36528815
[TBL] [Abstract] [Full Text] [Related]
20. outcomes of feeding jejunostomy after pancreaticoduodenectomy: A single-center experience.
Yamamoto N; Aoyama T; Murakawa M; Kamiya M; Shiozawa M; Rino Y; Masuda M; Morinaga S
J Cancer Res Ther; 2022 Dec; 18(Supplement):S444-S448. PubMed ID: 36511001
[TBL] [Abstract] [Full Text] [Related]
[Next]